CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE
$100 million Strategic Transaction Closed Plans to Submit New Drug Application for Ifetroban in DMD Top-Line Results Announced for Systemic Sclerosis Trial NASHVILLE, Tenn., Nov. 10, 2026 — Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused…
















